New data demonstrates robust efficacy of Vyepti in severe migraine

23 June 2025

Danish CNS specialist Lundbeck (LUND: CO) announced the full results from the Phase IV RESOLUTION trial at the 11th Congress of the European Academy of Neurology taking place in Helsinki, Finland.

The trial was a randomized, placebo-controlled trial designed to evaluate the efficacy of Vyepti (eptinezumab) versus placebo in patients with chronic migraine and associated medication-overuse headache who also received standardized patient education.

Patients with chronic migraine and medication-overuse headache represent a specific subset of the migraine patient population who are severely impacted by the condition. These patients are trapped in a cycle of worsening migraine, whereby escalating use of acute medication diminishes effectiveness, and exacerbates disease burden.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK